Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Editas Medicine (EDIT) in Focus: Stock Moves 5.1% Higher
Editas Medicine Inc. (EDIT - Free Report) was a big mover last session, as its shares rose over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Yesterday’s rally reverses the recent downtrend for the company, as the stock is now down almost 27% in the past one-month time frame.
Over the last 30 days, the company witnessed two negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Editas Medicine currently has a Zacks Rank #4 (Sell).
EDITAS MEDICINE Price
EDITAS MEDICINE Price | EDITAS MEDICINE Quote
A better-ranked biomedical stock is ANI Pharmaceuticals, Inc. (ANIP - Free Report) with a Zacks Rank #1 (Strong Buy).
Is EDIT going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>